Trial Profile

The PuMP Trial: "A Multistage Phase 1 Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of the Oncolytic HSV1 MVR-C5252 in Patients With Recurrent High-Grade Glioma"

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 07 May 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs MVR C5252 (Primary)
Indications Glioblastoma; Glioma
Focus Adverse reactions; Therapeutic Use
Acronyms PuMP

Most Recent Events

15 Apr 2026 Planned End Date changed from 1 Dec 2027 to 1 Dec 2028.
15 Apr 2026 Planned primary completion date changed from 1 Dec 2026 to 1 Dec 2027.
30 Apr 2025 Results (n=5) assessing safety, tolerability, and preliminary efficacy of MVR-C5252 delivered intratumorally via convection-enhanced delivery (CED), bypassing the blood-brain barrier, presented at the 116th Annual Meeting of the American Association for Cancer Research.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com